Mindset Partners With Canadian Psychiatric Research Hospital For Preclinical Study Of Psilocybin-Derived MSP-1014

Mindset Pharma Inc. (OTCQB: MSSTF), a drug discovery and development company creating next-generation psychedelic medicines for treating neurological and psychiatric disorders, has signed up for a research collaboration with the Centre for Addiction and Mental Health (CAMH), a health teaching and research institution collaborator of the World Health Organization (WHO) based in Toronto. 

The agreement goes as follows: Mindset will sponsor a preclinical trial at CAMH on its lead asset, MSP-1014. a novel and patented second-generation psilocybin-like compound being prepared for first-in-human studies alongside psilocybin.

Investigations have shown that a single dose of psychedelics can cause short as well as long …

Full story available on Benzinga.com

More Mindset Partners With Canadian Psychiatric Research Hospital For Preclinical Study Of Psilocybin-Derived MSP-1014